Sectors

In our 20+ years in the equity markets we have rarely seen such erratic moves on a daily basis across sectors and subindustries. While our portfolio has withstood the recent tremor, our confidence has taken the back seat with regard to our high-conviction calls for the year initiated in the December 2, 2019 report.1 Therefore we are closing out all high-conviction trades, both overweights and underweights, for a combined relative net gain of 27% (and average gain of 3.4%) since inception. In more detail, our underweight in homebuilders, preference of large caps to small caps and underweight in semi cap names have netted us 43%, 26%, and 6% in gains, respectively (see Charts 1& 2below). On the flip side, the overweight in banks and machinery and underweight in utilities have shaved off 25%, 13% and 12%, respectively (see Charts 1&2 below). Table 1 summarizes all our profits and losses. Further, from a portfolio management perspective we are instituting a rolling 10% stop from the highs on two extremely volatile cyclical positions in order to protect gains: our overweight in the S&P homebuilders index is up 51% since the October 2019 inception, and our large cap over small cap preference is up 45% since the May 2018 inception. Bottom Line: We are moving to the sidelines on the high-conviction calls for the year and are closing out all eight positions for a net gain of 27% (and average gain of 3.4%), since inception. Stay tuned. Chart 1 Chart 2   1     Please see BCA US Equity Strategy Weekly Report, “2020 Key Views: High-Conviction Calls” dated December 2, 2019, available at uses.bcaresearch.com.  

Overweight We recommend investors continue to take refuge in health care stocks within the defensive universe as the coronavirus pandemic unfolds. If severe government measures are a prerequisite to stop the spread of the virus then growth will suffer a massive setback. Were President Trump to eventually take draconian measures similar to what the Italian Prime Minister imposed recently, and to effectively shut down the country, then PCE will collapse. In fact, PCE excluding health care will take a beating. Health care outlays will rise both in absolute terms and relative to overall spending (see chart, second & third panels). Given the safe haven status of the S&P health care index and the stable cash flows these businesses command, when growth is scarce, investors flock to any source of growth they can come by and health care stocks definitely fit that bill. The implication is an earnings-led durable health care sector outperformance phase, a message that our relative macro EPS growth model is forecasting for the rest of the year (see chart, bottom panel). Bottom Line: We reiterate our overweight recommendation in the largest market capitalization weighted defensive sector in the SPX, the S&P health care sector. For more details, please refer to this Monday’s Weekly Report.  

Special Report

Dear Client, Next week we will be publishing a joint Special Report on the Chinese infrastructure investment outlook with our Emerging Markets Strategy service, authored by my colleague Ellen JingYuan He. Best regards, Jing Sima, China Strategist Feature Chart I-1Chinese Non-Financial Corporations Are Heavily Indebted There are fears that the two-month hiatus in China’s business activities due to the COVID-19 epidemic has sparked acute cash shortages among Chinese companies. In turn, this has increased the danger that the highly leveraged Chinese corporate sector may be pushed into widespread insolvency (Chart I-1). The number of bankruptcies will undoubtedly climb, but small and micro firms are most at risk versus larger companies that have deeper cash reserves and easier access to financing. Our analysis shows that, before the outbreak hit China in January, companies listed in China’s onshore and offshore equity markets exhibited relatively healthy financial statements with adequate operating cash flows to cover debt obligations. This increases the probability that Chinese listed companies will survive the economic and financial shocks from the epidemic, and that their stock prices will rebound along with the expectations of a recovery in the Chinese economy. Chart I-2Both Chinese Economy And Corporate Profits Are Largely Driven By Domestic Demand It also appears that China’s domestic economy is relatively insulated from the global financial market turmoil and impending global recession. China’s corporate profit outlook is dominated by domestic economic conditions rather than external demands. This view is also reflected in the relative performance of Chinese onshore and offshore stocks (Chart I-2). Moreover, the charts in the Appendix illustrate that corporate financial ratios in almost all sectors of China’s onshore and offshore equity markets have somewhat improved from the previous economic down cycle that began in 2014. This underscores our view that if reflationary measures overcompensate for the economic slowdown, as in the 2015/2016 easing cycle, then Chinese stocks will likely rally in absolute terms, as well as outperform global benchmarks. We selected three categories of financial ratios to monitor profitability, leverage and operating cash flow conditions of Chinese domestic and investable listed non-financial companies (Table I-1).1 The financial data in our exercise are from Refinitiv Datastream Worldscope. Its corresponding stock price indexes for China’s overall market and sectors most closely resemble the MSCI China Index and the MSCI China Onshore index. Table I-1 It is also noted that the Chinese investable index, excluding financial companies, is dominated by large technology companies such as Alibaba, Tencent, and Baidu.2 These tech companies generally have more adequate cash flows and lower debt ratios than the more capital intensive sectors such as industrial and energy. The analysis we present in this report on non-financial companies in the offshore market, therefore, is not indicative of China’s overall corporate financial health. Rather, our findings are indicative of how investors should view the listed companies and their sector performance within China’s investable market. Several observations from our analysis of the listed companies’ financial ratios are noteworthy: Chinese non-financial corporations are highly leveraged, and have not de-levered much despite the financial deleverage campaign that began in late 2017. Contrary to the belief that Chinese corporates’ financial health is significantly weaker than that in developed economies, the leverage ratio, profit margins, and debt-servicing ability among Chinese domestic and investable non-financial companies are actually in the range of their global peers (Chart I-3). Yet, Chinese companies trade at substantial discounts to global benchmarks. This is particularly evident in the offshore market, whereas domestic Chinese stocks were priced at a discount until the recent global market selloffs (Chart I-4). This underpins our view that, when China’s economy and corporate profits recover, Chinese stocks should outperform their global benchmarks on a cyclical time horizon. Importantly, with a stronger aggregate corporate financial health and a large price discount. Chinese investable non-financial stocks have more upside potential than their domestic counterparts. Chart I-3Financial Health Among Listed Chinese Companies Comparable With DMs Chart I-4Chinese Investable Stock Prices Remain Deeply Discounted Relative To Global Benchmarks   Utilities, machinery, industrials and construction materials are among the sectors with the lowest cash flow-to-interest expense ratios, in both China’s domestic and investable markets. In particular, machinery, industrials and construction materials are pro-cyclical sectors and their profit growth is positively correlated with economic growth. Their low profitability and high leverage contribute to their poor cash flows. Those sectors have been severely impacted by the stoppages in manufacturing and construction activities due to the COVID-19 epidemic in China, making them vulnerable to cash shortages. However, there is a low risk of a broad-based default among these firms, because state-owned enterprises (SOEs) dominate these sectors in the Chinese equity market. The stock performance in these sectors is also extremely sensitive to shifts in China’s monetary and policy stance, and thus should benefit from the recent loosening in monetary conditions and the push for a substantial increase in infrastructure investment this year. Chart I-5Small Property Developers In China Are Much More Vulnerable To Cash Shortages Than Large Ones The leverage ratio in the real estate sector has doubled in the past 10 years. The sector’s cash flow-to-total liabilities ratio has also declined sharply since 2017, when the authorities tightened lending standards to property developers. However, the sector’s aggregate cash flow situation is still an improvement from its lowest point in 2014, in both China’s domestic and investable markets. The countrywide lockdowns in January and February will undoubtedly have severe impacts on Chinese property developers’ cash flows. But the real estate sector is perhaps the best example in exhibiting a pronounced divergence in cash flow conditions between larger and smaller firms. Chart I-5 shows that, while the median ratio of cash-to-total liabilities tuned negative among 76 domestic listed real estate developers, the average ratio from total companies in the same sector suggests that the cash situation has actually improved since mid-2018. This divergence indicates that larger developers have more solid financial fundamentals and easier access to liquidity compared with their smaller counterparts, even before the lockdowns. We expect the divergence in cash flow conditions to widen in the coming months, and smaller property developers will face intensifying pressure to consolidate. China’s domestic healthcare companies have a much better cash balance than the investable healthcare sector, which has the lowest ratio of cash-to-interest expenses among all sectors. The poor cash flow conditions in investable healthcare companies are due to high leverage and low profitability, as well as high operating costs and R&D expenses. Chinese domestic healthcare sector has outperformed the broad market since the epidemic broke out in January. While we think the overall Chinese investable stocks have more upside than their domestic peers, domestic healthcare companies’ lower leverage ratio, stronger cash flows, and much higher profit margin make the sector a better bet than investable healthcare stocks on a cyclical time horizon (Chart I-6).  Chart I-6Domestic Healthcare Sector Likely To Continue Outperforming The Broad Market Chart I-7Energy Stocks Will Remain Depressed Until Oil Prices Rebound Historically, there has been a strong positive correlation between the energy sector’s profitability, cash flow conditions, stock performance and crude oil prices (Chart I-7). In the past two years, the sector’s leverage ratio has risen, profit margins have thinned and the cash flow situation has sharply deteriorated to the same level as in 2014 when oil prices collapsed. The ongoing oil price rout will generate powerful deflationary forces in the energy sector and will likely further deteriorate energy firms’ profitability and cash flow. While we stay long cyclical stocks versus defensives on both a 0-3 month and a 6-12 month view, we recommend a cautious stance towards energy stocks until the evolving oil price war situation is clarified.   Qingyun Xu, CFA Senior Analyst qingyunx@bcaresearch.com Jing Sima China Strategist jings@bcaresearch.com Appendix Overall Markets Excluding Financials Consumer Discretionary Sector Consumer Staples Sector Real Estate Sector Automobile Sector Machinery Sector Industrials Sector Construction Materials Sector Telecommunications Sector Technology Sector Healthcare Sector Energy Sector   Utilities Sector   Footnotes 1    We exclude banks and financial institutions from this analysis, due to discrepancy in Chinese banks’ accounting measures from those of non-financial corporations’. 2   Alibaba, Tencent, Baidu, and JD together account for nearly 40% of the non-financial market cap in Chinese investable index. Cyclical Investment Stance Equity Sector Recommendations

Equities were unhinged last week, as the trifecta of the corona virus becoming a pandemic, Saudi ripping the cord out of crude oil and the convulsing bond markets made for an explosive equity market cocktail. The result was two circuit breaker triggers last week and one yesterday near the -7% mark that (thankfully) worked as planned and brought some liquidity back into the markets. Our Complacency-Anxiety index plunged to a panic level that has marked previous equity market troughs (see chart). In yesterday’s Weekly Report, we also highlighted our capitulation index that is close to levels that have marked previous equity market troughs. We deem that a prolonged troughing phase will ensue leaving ample time for long-term investors to deploy capital. A retest near last Thursday’s and yesterday’s lows is a high probability event, at which point we think the market will likely hold those lows. Our bottoming out equity market roadmap is the 1987, 2011, 2015/16 and early 2018 drawdowns. Consolidation around recently depressed levels will serve as a signal to definitively put cyclical-oriented capital to work. Bottom Line: Investors with higher risk tolerance should be dipping their toes into market weakness and start to deploy long-term oriented capital.  

HighlightsPortfolio Strategy“There is blood in the streets”. Investors with higher risk tolerance should be buying into this weakness and start to deploy long-term oriented capital. S&P 500 futures fell to 2394 which is a whopping 1000 points below the February 19, 2020 high of 3393. We cannot time the bottom, but future returns will be handsome from current SPX levels.Stick with health care stocks as the coronavirus pandemic will boost demand for health care goods and services, at a time when investors will also seek the refuge of defensive equities as the economy is in recession.Surging demand for pharmaceuticals, firming operating metrics, cheap relative valuations, an appreciating greenback along with the drubbing in the global manufacturing PMI, all signal that an underweight stance is no longer warranted in pharma equities.    Recent ChangesLift the S&P pharmaceuticals index to neutral today. Table 1 Feature"Be fearful when others are greedy, and greedy when others are fearful"- Warren Buffett"The time to buy is when there's blood in the streets"- Baron RothschildEquities were unhinged last week, as the trifecta of the corona virus becoming a pandemic, Saudi ripping the cord out of crude oil and the convulsing bond markets made for an explosive equity market cocktail. The result was two circuit breaker triggers at the -7% mark that (thankfully) worked as planned and brought some liquidity back into the markets.Our Complacency-Anxiety index plunged to a panic level that has marked previous equity market troughs (Chart 1A). CNN’s Fear & Greed Index fell from near 100 to 1. While it could fall further at least a reflex rebound is in order. The Monday and Thursday mini-crashes felt like a capitulation (Chart 1B). Whoever wanted to get out likely got out. Chart 1ATime To Buy  Chart 1BThere’s Is Blood In the Streets Volumes in the SPX soared to the highest level since 2011 and the bullish percentage index1 fell to 1.4%2 below the low hit in 2008! Early last week six out of ten stocks in the broad-based Russell 3000 were down 30% or more from their 52-week highs. As a reminder, the SPX took the elevator down and erased 13 months of gains in a mere 13 trading days (Chart 2)! Chart 2Selling Is Overdone  Chart 3Our Roadmap A big crack has now formed.Given the tremor we just experienced, we doubt a V-shaped recovery to fresh all-time highs is in store for stocks similar to the one following the 2018 Christmas Eve lows V-shaped advance. Instead, parallels with the early-2018, 2015/16, 2011 or 19873 market action are more apt (Chart 3).Historically, Table 2 shows that the median time it takes for the stock market to make fresh all-time highs following a minimum 20% bear market from the most recent highs is two years. Table 2Bear Markets Duration In other words, this will likely be a prolonged troughing phase and a retest near last Thursday’s lows is a high probability event, at which point we think the market will hold those lows, and this will serve as a catalyst to definitively put cyclical-oriented capital to work.Our purpose here is not to scare investors when a number of markets are in duress and already in a bear market. We have been sending these warning shots4 since last summer5 all the way until the recent SPX February peak. Now that we have reached the proverbial “riot point” we would recommend taking a cold shower and keeping calm and collected in order to put things into perspective as one of our mentors would always do in tumultuous times.Importantly, investors with higher risk tolerance should be buying into this weakness and start to deploy long-term oriented capital. We cannot time the bottom, but future returns will be handsome from current SPX levels. As a reminder, S&P 500 futures fell to 2394 which is a whopping 1000 points below the February 19, 2020 high of 3393.This drubbing blew past our most bearish SPX estimate of 2544,6 pushing the SPX from overvalued to undervalued overnight. In fact, the forward P/E has fallen to one standard deviation below the historical time trend (Chart 4). Chart 4From Overvalued To Undervalued Our sense is that we will avoid a GFC type collapse, and thus investors with higher risk tolerance should start putting long-term cash to work as “there is blood in the streets”.Recapping the sequence of recent events is instructive. Two Fed officials (Clarida and Evans) made a huge error in our view by relaying that the Fed should stand pat and refrain from cutting rates. This culminated in a Powell press release that the Fed is ready to act, basically canceling these misplaced statements from the two Fed officials.Following these communication whipsaws, G7 finance ministers and central bankers held a conference call and then, the Fed panicked and cut rates inter-meeting further fueling the blazing fire. Now the Fed is cornered and has to act anew and further cut the fed funds rate (FFR) on March 18 all the way down to the zero lower bound. As a reminder, the last time the markets fell roughly 20% in late-2018 it took the Fed seven months to cut rates, this time it happened a mere two trading days after the market had a near 16% decline from the February peak.All of this bred uncertainty and a bond market spasm. There is little doubt we are in recession. The 10-year US Treasury yield plunging below 0.4% has fully discounted a recession, 100bps of Fed cuts and QE5 in our view.Keep in mind that the bond market now knows the Fed will cut the FFR to zero and eventually resort to QE, so it really front runs the Fed. This is something the bond market never anticipated or discounted on the eve of the Great Financial Crisis.While it is definitely true that interest rate cuts and further QE will neither cure COVID-19 nor reverse work-related disruptions, the Fed has to act and cut interest rates and restart QE for three reasons:a) to instill confidence that it is doing something and it is not a bystander,b) to loosen financial conditions as the VIX at a recent high near 76 and a more than doubling in junk spreads are screaming “help” (Chart 5), andc)  to jawbone the US dollar lower.Our sense is that the fixed income market hit an inflection point for stocks when the 10-year US Treasury yield breeched the 1.5% mark: the correlation between stocks and bond yields quickly snapped from negative to positive. Based on recent empirical evidence, stocks cannot stomach a 10-year US Treasury yield above 3%, and suffer indigestion below 1.5% (Chart 2). Crudely put, while lower yields act as a shock absorber for equities (via lifting the forward P/E multiple), below a breaking point they warn of a deflationary shock. Thus, we would view an eventual return of the 10-year US Treasury yield near the 1.5% as a positive sign for stocks. Chart 5Watching Spreads The other shock two weekends ago was the deflationary oil market spiral out of the OPEC meeting in Vienna where a fight apparently erupted between the Saudis and the Russians with regard to rebalancing the oil markets and resulted in $30/bbl oil. The timing could not have been worse. Oil related capex will fall off a cliff given the looming bankruptcies in the US shale oil patch (bottom panel, Chart 5) and that makes a fiscal package from the US even more pressing.We deem that only a mega fiscal package comparable to the $750bn TARP will definitively stop the hemorrhaging. A comprehensive fiscal package close to $1tn in order to deal with the aftermath of the corona virus would mark a bottom in the equity market.Health care stocks will benefit both from a fiscal package and from the corona virus pandemic automatic rise in demand for health care services and goods. Thus, this week we reiterate our overweight stance in the health care sector and make a small shift to our sub-sector positioning.Continue To Hide In Health Care…We recommend investors continue to take refuge in health care stocks within the defensive universe as the coronavirus pandemic unfolds. The S&P health care sector relative share price ratio recently bounced off the one standard deviation below the historical time trend line and is primed to vault higher in coming quarter (Chart 6). Chart 6Health Care Shines In Recessions If severe government measures are a prerequisite to stop the spread of the virus then growth will suffer a massive setback. Were President Trump to take draconian measures similar to what the Italian Prime Minister imposed recently and effectively shut down the country, then PCE will collapse.In fact, PCE excluding health care will take a beating. Health care outlays will rise both in absolute terms and relative to overall spending (Chart 7). Given the safe haven status of the S&P health care index and the stable cash flows these businesses command, when growth is scarce, investors flock to any source of growth they can come by and health care stocks definitely fit that bill.Not only is firming demand reawakening health care stocks that have been trading at a discount to the broad market owing to political uncertainty, but also their defensive stature is a heavily sought after attribute during recessions (Chart 6). Chart 7Upbeat Demand Profile…  Chart 8…Will Boost Selling Prices And Sales Inevitably, demand for health care goods and services will rise in the coming weeks straining the US health care system, as the number of infections increases. This will sustain industry selling price inflation and underpin revenue growth at a time when the world will be deflating (Chart 8).The implication is an earnings-led durable health care sector outperformance phase, a message that our relative macro EPS growth model is forecasting for the rest of the year (Chart 9).Importantly, such a rosy outlook is neither discounted in relative forward sales nor profit growth expectations for the coming year and we would lean against such pessimism (third panel, Chart 10). Chart 9Macro Profit Growth Model Says Buy  Chart 10Unloved And Under-owned Finally, valuations and technicals are both flashing green. On a forward P/E basis health care stocks still trade at a 15% discount to the broad market and momentum is washed out offering a compelling entry point for fresh capital.In sum, in times of malaise investors flock to defensive health care stocks, that are currently direct prime beneficiaries of the ongoing coronavirus pandemic.Bottom Line: We reiterate our overweight recommendation in the largest market capitalization weighted defensive sector in the SPX, the S&P health care sector.Upgrade Pharma To NeutralLift the S&P pharmaceuticals index to neutral from underweight for a modest loss of -1% since inception.A structurally downbeat pricing power backdrop was the primary driver of our bearish call on the S&P pharma index as both sides of the political aisle were out to get Big Pharma (bottom panel, Chart 11). This portfolio position was up double digits since inception, but it has given back almost all the gains recently since the coronavirus pandemic took stage a few weeks ago.While our thesis has not changed, we do not want to be bearish any health care related equities in times of a health epidemic. In addition, there is a chance that one of these behemoths discovers a compound to beat the virus and could serve as a catalyst for a sharp reversal of the downtrend.Importantly, from an operating perspective, margins appear to have troughed following 15 years of declines (middle panel,Chart 11). Now that inadvertently demand for medicines will surge, sales and profits will expand smartly (third & bottom panels, Chart 12). Chart 11It No Longer Pays To Be Bearish  Chart 12Firming Demand As a result of the coronavirus pandemic, we deem pharma factories will start to hum reversing the recent contraction in pharmaceutical industrial production (second panel, Chart 12).From a macro perspective, layoffs are inevitable from the coronavirus catalyzed recession and a softening labor market bodes well for defensive pharma profits (bottom panel, Chart 12).The collapse in the February global manufacturing PMI, primarily driven by China, is a window into what the future holds for developed market (DM) PMIs. DMs will feel the coronavirus aftermath in the current month and likely sustain downward pressure on the global manufacturing PMI print. Historically, relative forward profits and the global manufacturing PMI have been inversely correlated and the current message is to expect catch up phase in the former (global PMI shown inverted, middle panel, Chart 13).Moreover, the same rings true for the ultimate macro indicator, the US dollar. A rising greenback reflects global growth ills and a safe haven bid in times of duress as investors park their money in the reserve currency of the world. Therefore, defensive pharma relative forward EPS enjoy a positive correlation with the US dollar, and the path of least resistance remains higher (bottom panel, Chart 13).Finally, relative valuations are hovering near one standard deviation below the historical mean and technicals have returned back to the neutral zone underscoring that it no longer pays to be bearish pharma stocks (Chart 14). Chart 13Macro Backdrop Is Favorable  Chart 14Value Has Been Restored Adding it all up, surging demand for pharmaceuticals, firming operating metrics, cheap relative valuations, an appreciating greenback along with the drubbing in the global manufacturing PMI, all signal that an underweight stance is no longer warranted in pharma equities.Bottom Line: Lift the heavyweight S&P pharma index to neutral today, for a modest loss of -1% since inception. The ticker symbols for the stocks in this index are: BLBG: BLBG: S5PHAR – JNJ, MRK, PFE, BMY, LLY, ZTS, AGN, MYL, PRGO. Anastasios Avgeriou US Equity Strategistanastasios@bcaresearch.com Footnotes1     https://school.stockcharts.com/doku.php?id=index_symbols:bpi_symbols2     https://schrts.co/IfrNQmIu3    Please see BCA US Equity Strategy Daily Report, “Gravitational Pull” dated March 12, 2020, available at uses.bcaresearch.com.4    Please see BCA US Equity Strategy Weekly Report, “A Recession Thought Experiment” dated June 10, 2019, available at uses.bcaresearch.com.5    Please see BCA US Equity Strategy Special Report, “What Goes On Between Those Walls? BCA’s Diverging Views In The Open” dated July 19, 2019, available at uses.bcaresearch.com.6    Please see BCA US Equity Strategy Weekly Report, “From "Stairway To Heaven" To "Highway To Hell"?” dated May 2, 2020, available at uses.bcaresearch.com.Current RecommendationsCurrent TradesStrategic (10-Year) Trade RecommendationsSize And Style ViewsJune 3, 2019Stay neutral cyclicals over defensives (downgrade alert) January 22, 2018Favor value over growthMay 10, 2018Favor large over small caps (Stop 10%)June 11, 2018Long the BCA  Millennial basket The ticker symbols are: (AAPL, AMZN, UBER, HD, LEN, MSFT, NFLX, SPOT, TSLA, V).

The SPX collapsed on Monday in a mini-crash, reminiscent of the 20% October 1987 Black Monday crash. True, in 1987 the stock market fell 20% in a single day, but it is equally painful when the S&P 500 drops roughly 20% in 13 trading days, erasing 52 weeks of gains. While the equity market is extremely oversold and a short-term bounce is likely, we doubt a V-shaped SPX recovery looms similar to what prevailed following the 20% peak-to-trough December 2018 drawdown. Instead, 1987 (see chart), 2011, 2015/16 and early-2018 are the closest parallels we could think of, when the market had to digest those tremors over a three-to-six month troughing period. We deem the current equity market bottoming process will play out over the next two quarters leaving investors plenty of time to commence deploying long-term capital. Bottom Line: Stay patient before putting cash to work on a 9-12 month horizon, and for additional analysis please look forward to reading our upcoming Monday weekly report.  ​​​​​​​

Dear Client, In addition to this week’s report, BCA Research will hold webcasts over the coming days to discuss the economic and financial outlook amid the myriad of uncertainties gripping global markets. I will take part in a roundtable discussion alongside my fellow BCA Strategists Arthur Budaghyan, Mathieu Savary, and Caroline Miller for a live webcast on Friday, March 13 at 8:00 AM EDT (12:00 PM GMT, 1:00 PM CET, 8:00 PM HKT). In addition, I will hold a webcast on Monday, March 16 at 12:00 PM EDT (4:00 PM GMT). Best regards, Peter Berezin, Chief Global Strategist Highlights A global recession is now a fait accompli. The only question is whether there will be a technical recession lasting a couple of quarters, or a more prolonged downturn that produces a sizeable increase in unemployment rates. We lean towards the former outcome. Unlike during most recessions, the decrease in labor demand will be mitigated by a decline in labor supply, as potentially millions of workers are confined to their homes. This will limit the rise in unemployment, at least initially. The pandemic is likely to prompt firms to increase inventory levels for fear of further disruptions to their supply chains. This should provide a short-term boost to output. While it is possible that spending will remain broadly depressed even after the panic subsides, this seems unlikely. Private-sector finances were reasonably strong going into the crisis, while ultra-low government bond yields will incentivize increased fiscal outlays. Spending on leisure travel and public entertainment will remain subdued well into 2021, but much of this demand will be redirected to other categories of discretionary consumer purchases, particularly in the online realm. Health care expenditures will also increase. The collapse in oil prices following the breakdown of OPEC 2.0 represents a positive supply shock for the global economy, albeit one that will have negative consequences for oil-extraction sectors. We tactically upgraded stocks on the morning of Friday, February 28. That was obviously a major mistake: While global equities did rally 7% higher after our upgrade, they have since given up all their gains (and then some). For now, we are maintaining a modest overweight recommendation to equities. However, this is a low-conviction view, and we would not dissuade more conservative investors from reducing risk exposure. We would only consider upgrading stocks to a high-conviction overweight if the S&P 500 dropped to 2250, or the number of new infections outside of China peaked. In the meantime, we are downgrading high-yield credit tactically, as the odds of earnings weakness prompting a near-term rise in default expectations warrant caution. What A Way To Start The Decade So far, the 2020s may not be roaring, but they are certainly not boring. At the outset of the crisis, there were three scenarios for the COVID-19 outbreak: 1) A regional epidemic largely confined to China; 2) a series of global outbreaks, successfully short-circuited by a combination of government intervention and voluntary “personal distancing” measures; 3) A full-blown pandemic that exposes a significant proportion of the planet to the virus. Unfortunately, the first scenario has been ruled out. Policymakers are now trying to achieve the second scenario. Successful containment would “flatten the curve” of new infections, while allowing the sick to receive better treatment than they would otherwise. It would also buy precious time to develop a vaccine and increase the output of face masks, hand sanitizers, and other products that could slow the spread of the disease. Health Versus Growth Ironically, while the second scenario is clearly preferable to a full-blown pandemic from a health perspective, it may be more damaging from the very narrow, technical perspective of GDP accounting. It all depends on how severe the measures to quash each outbreak need to be. If simple hygiene measures and social distancing turn out to be enough, the economic fallout will be minimal. If ongoing mass quarantines and business closures are necessary, the damage will be severe. History suggests that containment efforts can work. During the Spanish flu, US cities such as St. Louis, which took early action to slow the spread of the disease, ended up with far fewer deaths than cities such as Philadelphia which did not (Chart 1). Western Samoa did not impose any travel restrictions and lost a quarter of its population. American Samoa closed its border and suffered no deaths. Chart 1Containment Efforts Can Be Effective: The Case Of The Spanish Flu Recent experience suggests that COVID-19 can be stopped, even after community contagion has set in. The number of new Chinese cases has fallen from 3,892 on February 5 to 31 on March 11. South Korea seems to be getting the virus under control. The number of new cases there has declined from 813 on February 29 to 242 (Chart 2). Japan and Singapore also appear to be succeeding in preventing the virus from spreading rapidly. Chart 2Coronavirus: The Authorities In East Asia Seem To Be In Control Of The Situation What remains unclear is whether other countries can replicate East Asia’s experience. A recent Chinese study estimated that R-naught – the average number of people someone with the virus ends up infecting – fell from 3.86 at the outset of the outbreak to 0.32 following interventions (Chart 3).1 In other words, China was able to lower R-naught to one-third of what was necessary to stabilize the number of new infections. If one wanted to be optimistic, one could argue that other countries could get away with less heavy-handed measures, even if it is at the expense of a somewhat slower decline in the infection rate. Chart 3Severe Containment Measures Have Changed The Course Of The Wuhan Outbreak Unfortunately, given how contagious the virus appears to be, it is unlikely that simple measures such as regularly washing one’s hands, avoiding large gatherings, and wearing a face mask in public when sick will suffice. Trade-offs will have to be made between growth and health. Moreover, if the virus becomes endemic in a few countries that do not have the institutional capacity to contain it, this could create a viral reservoir that produces repeated outbreaks in the wider world. The result could feel like a ghastly game of whack-a-mole. The Fatality Rate The degree to which countries pursue costly containment measures depends on how deadly the virus turns out to be. On the one hand, there is some evidence that the fatality rate from COVID-19 is lower than the 2%-to-3% that has been widely reported once mild or asymptomatic cases, which often go undetected, are taken into account. This may explain why South Korea, which has arguably done a better job of testing suspected patients than any other country, has reported a fatality rate of only 0.7%. Like the seasonal flu, the death rate from COVID-19 appears to be heavily tilted towards the elderly. In Italy, 89% of COVID-19 deaths have occurred among those who are 70 and older. On the ill-fated Diamond Princess cruise liner, not a single person under the age of 70 has died. The fatality rate for passengers on the ship older than 70 is 2.4%. The seasonal flu kills about 1% of those it infects over the age of 70. Based on this simple calculation, COVID-19 is more lethal, but not light-years more lethal, than the typical flu (and possibly less lethal than the flu is for young children). Unfortunately, these optimistic estimates assume that patients with COVID-19 can continue to receive appropriate care. As we saw in Wuhan, where the official death rate stands at 4.5% compared to 0.9% in the rest of China, and as we are now seeing in Italy, once the health care system becomes overwhelmed, death rates can rise sharply. Bottom Line: Containing the virus will be economically costly, but given the potentially large death toll from a full-blown pandemic, most countries will be willing to pay the price. A Global Recession Even before the virus became endemic outside China, we estimated that global growth would fall to zero on a quarter-over-quarter basis in Q1. As we cautioned back then, the risk to our forecast was tilted to the downside, and that has proven to be the case. We now expect the global economy to shrink not just in the first quarter but in the second quarter as well, as country after country experiences a surge in new infections. Two consecutive quarters of negative growth constitute a technical recession. Despite the drop in new cases in China over the past two weeks, most high-frequency measures of economic activity such as property sales, railway-loaded coal volumes, and traffic congestion have yet to return anywhere close to normal levels (Chart 4). In the US, hotel occupancy rates, movie ticket sales, and attendance at sporting events were all close to normal levels as of last week. However, that is changing quickly. Already, automobile traffic in Seattle, one of the cities most hard-hit by the virus, has fallen sharply (Chart 5). Chart 4China: It Will Take Time For Life To Return To Normal Chart 5US: Staying Home More In Seattle Due To The Virus? Qualitatively Different While a recession in the first half of 2020 is now unavoidable, the nature of this recession is likely to be quite different than in the past. To understand why, it is useful to review what causes most recessions. A typical recession involves a prolonged loss of aggregate demand. Such a loss of demand can result from either financial market overheating or economic overheating. Financial market overheating can occur if a credit-fueled asset bubble bursts, leaving people with less wealth struggling to pay off debt. For example, US residential investment fell from 6.6% of GDP in 2005 to 2.5% of 2010. Thus, even after the credit markets thawed, there was still a large hole in aggregate demand that needed to be filled. A similar, though less severe, loss of demand occurred when the bursting of the dotcom bubble led to severe cutbacks in IT spending. Economic overheating occurs when a lack of spare capacity puts upward pressure on inflation. Wary of accelerating prices, central banks slam on the brakes, raising interest rates into restrictive territory. This often results in a recession. In both types of recessions, there are usually second-round effects that can swamp the initial shock to aggregate demand. As spending falls, firms start to lay off workers. The resulting loss in household income leads to less spending. Even those who retain their jobs are apt to feel less confident, leading to an increase in precautionary savings. For their part, businesses tend to cut production as inventory levels swell. Things only return to normal once enough pent-up demand has accumulated and/or policy has become sufficiently stimulative to revive spending. Framed in this way, one can see that the current downturn differs from past downturns in at least three important respects. First, unlike during most recessions, the decrease in labor demand this time around will be partly mitigated by a decline in labor supply, as potentially millions of workers are confined to their homes. While this will not prevent many workers from temporarily losing income, it will limit the increase in unemployment, at least initially. We have already seen this in China, where GDP growth collapsed but companies are complaining about a shortage of migrant labor. Second, rather than falling, inventory levels may actually rise. Since companies will have to deal with pervasive supply shocks of unknown frequency, duration, and magnitude, their natural inclination will be to increase inventory levels for fear that they will not be able to access their supply chains when they need them. If recent reports of hoarding of toilet paper and bottled water are any guide, the same sort of behavior will show up among consumers. Again, in the short term, this additional demand will help to keep unemployment from rising as much as it would otherwise. Third, and perhaps most importantly, the ongoing crisis is the result of an exogenous shock rather than an endogenous slowdown. In fact, a variety of economic indicators such as US payrolls, the Chinese PMI, and German factory orders were all pointing to an acceleration in global growth before the crisis began. This suggests that growth could recover quickly once the panic subsides. While it is impossible to say with any degree of certainty how long it will take for the panic to end, it may not last as long as many fear. Investors should particularly pay attention to the situation in Italy. If the number of new cases peaks there, it could create a sense that other western countries will be able to get the virus under control. Second-Round Effects? Although it is possible that economies will remain depressed even after the panic subsides, this seems unlikely. Private-sector finances were reasonably strong going into the crisis. The private-sector financial balance – the difference between what companies and households earn and spend – is in surplus in most countries, including China (Chart 6). Chart 6The Private Sector Spends Less Than It Earns In Most Economies Chart 7Lower Oil Prices Eventually Lead To Higher Growth Granted, not all sectors are likely to prove equally resilient. Spending on leisure travel and public entertainment will remain subdued well into 2021. The collapse in oil prices following the breakdown of OPEC 2.0 will also wreak havoc on oil producers. In both cases, however, there will be offsetting benefits. Much of the demand for travel and entertainment will be redirected to other categories of discretionary consumer purchases, particularly in the online realm. And while lower oil prices will hurt producers, they represent a boon for consumers and companies that use petroleum as an input. In general, as Chart 7 illustrates, global growth usually accelerates following declines in oil prices. Fiscal Policy Will Turn More Stimulative Even before the crisis began, we argued that most governments should permanently increase fiscal deficits in order to raise the neutral rate of interest. At the current juncture, with a recession upon us and government bond yields at ultra-low levels, the failure to enact meaningful fiscal stimulus would be economic malpractice of the highest order. In addition to easing measures being rolled out by central bankers, our sense is that we will get a lot of fiscal stimulus, sooner rather than later. During most recessions, there is always a chorus of voices from people whose own jobs are secure about how a downturn is necessary to cleanse the system. This time around, it is obvious that the victims are not to blame. Politicians will not endear themselves to voters by denying the need for fiscal support to households struggling with medical bills and lost time from work and businesses facing bankruptcy. President Trump’s pledge this week to cut payroll taxes and increase transfers to those affected by the virus is just a taste of what’s to come. Investment Conclusions Chart 8Stock-To-Bond Ratio: A Lot Of The Bad News Has Already Been Priced In We tactically upgraded stocks on the morning of Friday, February 28. That was obviously a major mistake: While global equities did rally 7% higher after our upgrade, they have since given up all their gains (and then some). In retrospect, we should have paid more attention to our own analysis in our report “Markets Too Complacent About The Coronavirus.” For now, we are maintaining a modest overweight recommendation to equities. The total return ratio between stocks and bonds has fallen by a similar magnitude as in the run-up to prior recessions, suggesting that much of the bad news has already been priced in (Chart 8). Nevertheless, significant downside risks remain, which is why we would characterize our equity overweight as a fairly low-conviction view. We would not dissuade more conservative investors from reducing risk exposure. As discussed above, containing the virus could lead to significant economic disruptions. We would only consider upgrading stocks to a high-conviction overweight if the S&P 500 dropped to 2250, or the number of new infections outside of China peaked. In the meantime, we are downgrading high-yield credit tactically, as the odds of earnings weakness prompting a near-term rise in default expectations warrant caution. Safe-haven government bond yields will probably not rise much from current levels, at least in the near term. The Fed cut rates by 50 basis points last week and will cut rates by another 50 basis points next week. Looking further out, however, bonds are massively overvalued and will suffer mightily as life returns to normal.   Peter Berezin Chief Global Strategist peterb@bcaresearch.com   Footnotes 1Chaolong Wang, Li Liu, Xingjie Hao, Huan Guo, Qi Wang, Jiao Huang, Na He, Hongjie Yu, Xihong Lin, Sheng Wei, and Tangchun Wu, “Evolving Epidemiology and Impact of Non-pharmaceutical Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China,”medrxiv.org, March 6, 2020. Global Investment Strategy View Matrix MacroQuant Model And Current Subjective Scores Strategic Recommendations Closed Trades

There is a lot of uncertainty that reverberates through the equity markets and the dust has yet to settle down from Monday’s big crack. Small caps (similar to weak balance sheet stocks, middle panel) have cratered for three reasons: First, they are massively indebted as the bottom panel of the chart shows not only in absolute terms, but also compared with their large cap brethren. Second, small caps have been mired in earnings deflation for a while and the looming recession now aggravates the fall in these high beta stocks. Finally, small caps have a large weighting in financials in general and small regional banks in particular. As such, the recent double whammy of the oil price collapse and bond yield plunge has wreaked havoc in small cap indexes. We have been cyclically avoiding small caps and instead preferring large caps since mid-2018 and late-last year we also added this size preference to our high-conviction call list as a modest hedge to most other high-conviction calls that were levered to higher interest rates. Today, from a portfolio risk management perspective, we are instituting a trailing stop at the 10% return mark in order to protect gains. Bottom Line: Stick with the large cap bias for a while longer.